Genetic Idiotypic and Tumor Cell-Based Vaccine Strategies for Indolent Non Hodgkin's Lymphoma

E-ISSN： 1875-5631|5|5|511-521

ISSN： 1566-5232

Source： Current Gene Therapy, Vol.5, Iss.5, 2005-10, pp. : 511-521

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bendamustine: A Review of its Use in the Management of Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

By Garnock-Jones Karly P.

Drugs, Vol. 70, Iss. 13, 2010-09 ,pp. : 1703-1718

Adis International

Access to resources Recommend Favorite

Bendamustine: A Review of its Use in the Management of Indolent Non-Hodgkin Lymphoma

By Plosker Greg L. Carter Natalie J.

Drugs, Vol. 68, Iss. 18, 2008-01 ,pp. : 2645-2660

Adis International

Access to resources Recommend Favorite

Fludarabine–Mitoxantrone–Rituximab regimen in untreated indolent non‐follicular non‐Hodgkin's lymphoma: experience on 143 patients

Hematological Oncology (Electronic), Vol. 278-0232, Iss. 3, 2015-09 ,pp. : 141-146

John Wiley & Sons Inc

Access to resources Recommend Favorite

Fludarabine–Mitoxantrone–Rituximab regimen in untreated indolent non‐follicular non‐Hodgkin's lymphoma: experience on 143 patients

Hematological Oncology (Electronic), Vol. 33, Iss. 3, 2015-09 ,pp. : 141-146

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bendamustine: A Review of its Use in the Management of Chronic Lymphocytic Leukaemia, Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma and Multiple Myeloma

By Hoy Sheridan M.

Drugs, Vol. 72, Iss. 14, 2012-10 ,pp. : 1929-1950

Adis International

Access to resources Recommend Favorite